Andy Blidy

T, B, & NK cells and Stem cell scientist for 50 yrs , Commercialized CD4/IL-2r, CD34 Mabs at BDMC &ABI TaqMan mRNA Gene Expression during human genome project.

[Andy Blidy @ablidy]

A couple of California stem cells supporters..... Colby Leis my grandson making a statement https://t.co/WW677rjV7R with Grandpa

[Andrew Caravello, DO @andrewcaravello]

🧬 Dendritic cells are my beat, #DCVax and $NWBO included, and I am flagging that up front so you can discount me for it. The study below is independent of all of that. The engine is my own, and it stands on the evidence I cite, not on the position.

A cheap blood number almost everyone already has in their chart can tell you how fast you are aging, whether a critically ill patient will survive the week, and whether a tumor would find them easy ground. It has been sitting in plain sight for years. Here is what it is, why it works, and why it points at something far larger than any single test.

At #ASCO26, Dr. Parham Habibzadeh (@HabibzadehMD) presented work on clonal hematopoiesis and the risk of developing cancer, from his group at @UPMCnews and @PittHealthSci. It connects directly to the paper he published with John Sorkin and Dennis Hsu in Cancer Medicine, and to the long-form essay I built on top of it. Full credit to that team. What follows is the bridge from their finding to the engine I believe it is reading.

Start with two people and two numbers.

Maria is thirty-four and runs most mornings. A routine draw gives her a red cell distribution width of 12.8 and an albumin of 4.6. Frank is sixty-eight and arrives in an emergency room short of breath, with the same two numbers at 16.5 and 3.1. Divide one into the other and you get a single figure, the RDW to albumin ratio, RAR. Maria sits at 2.78. Frank sits at 5.32.

Two numbers nearly everyone already has. No new assay, no new machine. The reason to combine them is simple. Under chronic inflammation RDW climbs while albumin falls, so dividing a rising number by a falling one swings the result harder than either moves alone. Frank’s RDW is only 29 percent above Maria’s and his albumin only 33 percent below hers, yet his ratio is 91 percent higher. That amplification is the whole point.

The founding study asked a narrow question no one had answered cleanly: is RAR tied to specific common cancers, one at a time, in an ordinary population rather than only in the sickest hospital patients. Using NHANES, pooling cycles from 2005 to 2018, the team worked with 37,373 adults, matching each recent cancer case to cancer-free controls on age, sex, and race. A higher RAR was clearly associated with recent lung, colorectal, and breast cancer, the signal strongest in lung. For prostate cancer there was nothing. The same cheap ratio that lit up for three cancers stayed flat for the fourth. Hold onto that null, because it turns out to be the most informative line in the paper.

Why should a ratio of two ordinary blood values know anything about a tumor? Because both halves are pushed by one molecule. Interleukin-6, IL-6, interferes with red cell maturation in the marrow, which scatters their sizes and lifts RDW, and in the liver it triggers the switch that drops albumin. The two halves of RAR are not two findings. They are two footprints of the same foot. And the arrow runs from IL-6 outward, not merely alongside. People who inherit weaker IL-6 signaling carry lower inflammation and higher hemoglobin, the profile of someone on an IL-6 blocker dealt by nature. In rheumatoid arthritis, the IL-6 blocker tocilizumab was the one agent that raised hemoglobin where others did not. And in mice carrying an IL-6-producing human lung cancer, blocking IL-6 reversed both the disordered red cells and the fallen albumin at once, while leaving the tumor untouched.

IL-6 comes in two forms that do opposite work, and this is the hinge. Classic signaling is brief, self-limiting, and on balance calming. This is the IL-6 a runner makes, which is why Maria can generate floods of it and take no harm. Trans-signaling is chronic, does not resolve, and can switch on almost any cell in the body. This is IL-6 as noise. RAR is biased toward reading the noise, because only sustained noise can reshape the slow-turning red cell population and lower the liver’s baseline. The blood test is, in effect, a noise meter. Population data agree: physically active people carry lower RDW than sedentary people, independent of iron. And we now have a drug, olamkicept, that blocks only the noise and spares the message, working without the immune suppression of shutting IL-6 down entirely.

Follow that noise downstream and you reach the engine. Senescent cells, old cells that will not divide and will not die, leak a steady inflammatory stream, and IL-6 is one of its loudest parts. That noise switches on STAT3. Chronically active STAT3 recruits silencing enzymes onto a gene called IRF8 and locks it shut. IRF8 is the master switch for one specific immune cell, the cDC1 dendritic cell, the immune system’s teacher. Its job is to instruct the body’s killer cells through a signal called IL-12. Lock IRF8, and the teacher goes silent, the instruction stops, and a fully staffed immune system loses the one cue that tells it where to point. That silence, repeated across decades, is what we feel as aging, and it is the open door through which cancer walks.

This is not a stack of guesses. Every step has been caught in the act by separate labs, much of it in human cells. Inflammation activates STAT3. STAT3 drives the silencing of IRF8, with human colorectal tumors showing exactly that pattern of raised silencing enzymes and muted IRF8. Knock IRF8 down in young human monocytes and you reproduce the aged defect. Restore it in old ones and the defect repairs. Put the dendritic-cell master factors, IRF8 among them, back into a cancer cell, and it reprograms into a working immune teacher. Nobody set out to build the whole chain. The pieces simply kept fitting the ones beside them.

There is a deeper way to read the red-cell half, and it joins the gauge to the engine at the marrow. Under chronic inflammatory drive, the marrow abandons balanced production for a crisis program, pouring out suppressive myeloid cells while starving the teacher line. This is emergency myelopoiesis, and IRF8 sits at the fork where a young marrow cell chooses its fate, pushing it toward the teacher and away from the suppressors. So the same switch is silenced in two places at once, in the mature teacher and in the progenitors that should have become teachers. A rising RDW is a sign the marrow has begun building suppressors where it should be building teachers. RAR is a cheap way to read which program the factory is running.

This is exactly where Dr. Habibzadeh’s clonal-hematopoiesis work meets the ratio. With age, blood-forming stem cells acquire mutations that let them outgrow their neighbors, and the two most common mutated genes, DNMT3A and TET2, sit on the very switch that silences IRF8. Such a clone is not a passive bystander. It pours out inflammatory signal of its own, so the marrow becomes a source of the field rather than only its victim, a loop in which the noise selects the clone and the clone makes more noise. And it disorders red cell production directly, which is why, across more than thirty thousand people in three biobanks, an RDW at or above 15 was among the strongest signs that a clonal marrow was drifting toward overt disease. A high RDW can mark not just a marrow pushed from outside, but a marrow manufacturing the push itself. That is the same biology being put forward as a tool to identify cancer risk.

Now the prostate null makes sense. A field that silences the teacher can only be read where a field is generated. Many prostate cancers stay small, local, and quiet, raising no systemic alarm, so the gauge does not move. RAR reads the field, not the address. My framework was fixed before this paper existed, and it forbids the needle moving in an indolent, contained cancer. The prostate null is exactly the result it would have called in advance. A theory bent to fit data forbids nothing. This one forbids that, and the paper obliged. That is the difference between a slogan and a result.

Read against age, a single RAR draw gives two readings at once. Picture a tide with waves on it. The tide is inflammaging, the low-grade inflammation that rises a little every year in everyone. The waves are whatever loads the field right now, a tumor, an infection, a flare. The level compared to your age is a biological aging clock. The amount standing above what your age predicts is a disease-activity flag. One number, split into two meanings by a single question: how old are you. Maria’s 2.78 is low tide and no wave. Frank’s 5.32 carries some tide from his years but stands far above even an aged man’s expected level, so a wave is breaking.

It also separates two temperatures people confuse. The local temperature is the tumor’s own neighborhood, hot if killer cells have infiltrated it, cold if it is an immune desert. The systemic temperature is the inflammatory tone of the whole bloodstream, and that is what RAR reads. The engine links them: the same field that lifts RAR silences the teacher and lets suppressor cells multiply, and since the teacher is the cell that recruits the killers that warm a tumor, a high systemic field is a cold-making field. This predicts, and clinics observe, that patients with high systemic inflammation respond worse to immune therapies. A high RAR is a hint the body’s own climate is cooling its tumors.

And it explains why RAR predicts death across so many unrelated acute settings. Red cells live about four months, so RDW moves slowly and cannot leap overnight. When a patient arrives acutely ill with an already-high RDW, that height was there before they walked in. It reports their standing baseline, their reserve, the cushion they carry to absorb a shock. The number does not report tonight’s pneumonia. It reports the depleted ground the pneumonia landed on. That is why one ratio tracks outcomes in sepsis, heart attack, kidney cancer, the general population, and now these solid tumors. If those were truly separate machines, no single blood ratio should follow all of them.

The hardest objection deserves stating at full force: a cheap marker of inflammation and nutrition will track bad outcomes everywhere, so universality alone proves no shared engine. Conceded. The idea does not lean on universality. It leans on two separable claims. The practical one, that RAR is a cheap, reproducible gauge of inflammatory and nutritional stress ready to use today, owes nothing to the theory and is already established. The mechanistic one, that the field RAR reads acts through the IRF8 and cDC1 instruction limb, is the bolder claim, and it rests on a documented chain. When you remove standard inflammation markers, RDW does not lose its signal, it remains the strongest predictor in long-term cohorts where C-reactive protein fades. And when researchers asked which plasma proteins carry the link between high RDW and death, several were tied to cellular senescence, the engine’s own signature found by a method that knew nothing of this framework.

Now step all the way back, because this is the part that matters most. Every other measure of aging is an odometer. The epigenetic clocks count methylation already drifted. The telomere records divisions already spent. They read distance traveled, what is already behind you. RAR is not an odometer. It is a pressure gauge. It reads the force still being applied, the pressure on the engine, and a pressure, unlike a distance, can be released. The same number can fall in the same person, over months, when the field that drives it comes down, by exercise that makes the message and not the noise, by a drug built to silence only the noise, by anything that quiets the senescent furnace. It is not recording what has already happened to the body. It is reporting the pressure the body is under now. A clock tells you the hour. This gauge tells you whether the hands are still being pushed, and lets you watch them slow.

That is the instrument a reversible theory of aging requires, and almost none of it needs a new study to test. RAR rides on the two most frequently measured numbers in medicine, already sitting in enormous public datasets with outcomes attached, in the best cases with the engine’s own deeper markers lying right beside them. The national survey behind the founding paper has mortality linkage. Public intensive-care databases can test the reserve claim head-on. The UK Biobank proteomic project has the engine’s readouts next to each person’s RDW, albumin, and years of cancer and death records. The decisive experiment is not a future trial. It is a query against data that already exists.

This is why the book matters, and why I wrote it. A cheap blood number is only a curiosity until something tells you it is reading one machine. The Biological Reboot is that something. It is the work that assembles the independently proven pieces into a single mechanism: that aging is not mainly the accumulation of damage but the loss of immune instruction, a teacher cell silenced by a pressure field through the IRF8 and cDC1 and IL-12 cascade. It lays out the cascade lock by lock, names what is proven and what is still synthesis with a section given over to what it does not yet prove, and it makes the claim the clocks cannot: that the silence can be lifted. If the core lesion is a teacher held quiet under pressure rather than damage already done, then the lesion is reversible, the pressure is the part you can change, and a gauge of that pressure is how you would know it was lifting. The paper gives you the number. The book tells you it is one machine, why the needle climbs, and what to do when it does. One without the other is half the picture.

One ratio. One engine behind aging, cancer, chronic disease, and the inflammatory part of acute illness. A gauge cheap enough to place on every blood test already drawn, and a framework that tells you what it means.

Credit where it belongs: the founding study is the work of Parham Habibzadeh, John Sorkin, and Dennis Hsu, Cancer Medicine, out of @UPMCnews and @PittHealthSci.

The Biological Reboot: The Dendritic Cell Theory of Aging

📖 <https://t.co/HxrrM3z2I0>

#ASCO26 #cancer #cancerresearch #clonalhematopoiesis #immunology #aging

[Science Immunology @SciImmunology]

Better understanding of #chromatin-based regulatory mechanisms in #macrophages could guide future therapeutics to combat chronic diseases, suggests a new Review.

Learn more in Science #Immunology: https://t.co/MYOZv9Edxy

[Cell @CellCellPress]

In the latest issue! Mesenchymal drift: A convergent framework for the hallmarks of aging https://t.co/hKVJjX6ptd

[UPMC Hillman Cancer Center @UPMCHillmanCC]

If you’re headed to the final day at #ASCO26…check out Dr Parham Habibzadeh’s (@HabibzadehMD) oral presentation on clonal hematopoiesis in identifying risk in developing #cancer. #cancerresearch
Wednesday| Jun 2| S100b| 9:45-12:45 @UPMCnews @PittHealthSci

[World of Science @Science_TechTV]

Scientists use CRISPR to remove HIV DNA from human cells in the lab, a major step toward a potential cure.

[Harshi Peiris, Ph.D. @Neuroscope_mp]

We've spent decades hunting for "the ALS cure."

I get it … when you're facing this disease, you want one answer. That's human.

But after 20 years in neurodegeneration, I can tell you: we've been asking the wrong question.

And new science proves it. Here's what's actually going on.

#ALSAwareness #PrecisionMedicine

[Michael Bigger @biggercapital]

King’s College The House of Dr. Ashkan

[Amanda Hollensbe (Braelyn’s Mom) @HollensbeAmanda]

King’s College Hospital.

Not exactly a place anyone puts on a London bucket list, yet for Braelyn and me, it may end up being one of the most important destinations in the city.

Most visitors come to London to see palaces, cathedrals, castles, and Crown Jewels. We came here for treatment at this hospital under Prof. Ashkan and his team, including Dr. Mehra and Dr. Prasad. While that is the reason for our journey, we are incredibly grateful that it has brought us to one of the world’s most famous and historic cities, allowing us to experience its remarkable sights, stories, and history along the way.

This past weekend, we walked through nearly a thousand years of British history at Westminster Abbey, Buckingham Palace, and the Tower of London. Today we walked into a place where the future is being written. One preserves treasures from the past; the other is working to create more time for families like ours.

King’s College Hospital may not be as famous as Tower Bridge or Westminster Abbey, but for us, it represents something even more valuable:

Hope.

And after everything Braelyn has endured over the last three years, hope is a destination worth traveling 4,000 miles to find. ❤️🇬🇧🇺🇸
#DCvaxForBraelyn #DCvax $NWBO

[Harshi Peiris, Ph.D. @Neuroscope_mp]

🚨 Scientists just identified a hidden 'molecular switch' that drives chronic brain inflammation in Alzheimer’s.

It’s a protein called STING that gets chemically stuck in the “on” position.

This could be a major new drug target. Thread 👇

[Amanda Hollensbe (Braelyn’s Mom) @HollensbeAmanda]

@Investisco

[Andy Blidy @ablidy]

@Neuroscope_mp @ScienceNews So what is the mechanism of effectiveness, from immunologic and molecular process…… ie how does it work ? What cells does affect ? How does it affect IL-12 , IrF8 , stat3 , ?

[Harshi Peiris, Ph.D. @Neuroscope_mp]

I worked at Revolution Medicines, and this is indeed a great option for pancreatic cancer from them.

My focus was on biomarkers for KRAS cancers and drug combination approaches (lung and colon).

Here’s my two cents based on that.

1. KRAS is notorious for creating cancer heterogeneity. They can include different mutations downstream over time.
2. Due to the point I made in #1 … the same patient can have two different tumors with different mutations.
3. Drug combinations are tricky and always result in toxicity.
So yes … the drug will be effective if caught early.

I still believe precision medicine is the way forward … and this drug is one important treatment option that can be added to make personalized treatment options for cancer patients.

[Andrew Caravello, DO @andrewcaravello]

@ablidy @grok what are the implications for #RareGeneticDisease and #GeneTherapy

[Amanda Hollensbe (Braelyn’s Mom) @HollensbeAmanda]

On our way to the pre-apheresis appointment right now!

[Andy Blidy @ablidy]

@parmita Need to reboot the immune system with alpha DC1 cultured cells

[Harshi Peiris, Ph.D. @Neuroscope_mp]

Quick 60-second breakdown: why some brains are biologically wired to resist GLP-1 drugs like Ozempic. It’s not willpower — it’s neuroscience. 🧠
https://t.co/zsE0MhAkM3
Full thread pinned above

[Andy Blidy @ablidy]

A little history why reboot is necessary before any treatments

Andy Blidy is the co-author with Andrew Caravello, DO, of the 2026 preprint The Biological Reboot: How the Alpha-Type-1 Polarized Dendritic Cell Restores Bidirectional Immune Instruction (and related book). My contributions span decades, bridging foundational flow cytometry, epigenetic/chromatin biology, neuro-immune systems thinking, and modern integrative immunology.
1. Foundational Immunology (1990)As previously detailed: Co-author (with Anne Jackson as lead) of the landmark paper “Restricted Expression of p55 Interleukin-2 Receptor (CD25) on Normal T Cells” (Clinical Immunology and Immunopathology, 1990). This work demonstrated constitutive CD25 expression on ~30% of resting CD4+ T cells using advanced flow cytometry (FACScan with PE-conjugated antibodies developed/commercialized at Becton Dickinson). It provided the observable population that later enabled identification of natural regulatory T cells (Tregs) and their role in the bidirectional DC-CD4 regulatory circuit.
2. DNA/Chromatin, Epigenetics & Systems Biology (2005 DARPA/Ki Biotechnology Work Blood Pharming )In March 2005, Blidy (with Ray Jacolik and John Cardott at Ki Biotechnology) authored/presented a forward-looking conceptual framework for DARPA-style next-generation sensing and self-repair technologies :Title: Defining the Eye or Skin as the Window for Monitoring the Neuro-Immune System as Real-Time Molecular Functions. Core themes (directly relevant to today’s work):
DNA/chromatin and epigenetic regulation: Extensive discussion of DNA methylation, chromatin modification, nucleosome packaging, histone octamers, euchromatin/heterochromatin dynamics, replication timing during S-phase, and epigenetic inheritance. It explores how these maintain or alter gene expression patterns (e.g., CpG methylation as a repression marker) and proposes functional gene networks/modules for DNA damage response, repair (nucleotide excision, double-strand breaks), and cellular modules linking proliferation, apoptosis, signal transduction, and immune defense.
Real-time molecular monitoring and self-repair: Vision for non-invasive monitoring (retinal scan via the eye or skin-based RF/biowires) of immune responses at the DNA/molecular level. Detection of CBRN exposure or hazards via changes in immune-system DNA expression/methylation patterns, triggering self-repair through inflammatory/immune activation.
Neuro-immune-electric integration: Links brain electricity (voltage, rhythm, synchrony, brain waves), neurotransmitters (dopamine, acetylcholine, etc.), and their influence on immune function. Neurons, synapses, and biochemical signaling as part of a broader bio-electrical network interfacing with immunity.
Bio-inspired nanotechnology & systems biology: Self-assembling DNA/peptide nanostructures, gene networks (functional rather than just physical linkages), grid computing for real-time data, and holistic “systems biology” approaches that integrate genomics, proteomics, and immune responses across scales—from single molecules to whole-organism fitness.
This 2005 work demonstrates Blidy’s long-standing focus on upstream epigenetic control (chromatin states, methylation) of immune regulation and the body’s capacity for adaptive, self-repairing molecular responses—concepts that directly prefigure and support the Caravello–Blidy Dendritic Cell Theory of Aging.3. Role in the Current Caravello–Blidy Framework (2026)Blidy supplies historical + mechanistic continuity:
The 1990 CD4+CD25 pillar (Treg side of the loop).
The 2005 chromatin/epigenetic + real-time neuro-immune monitoring perspective, which aligns with the preprint’s emphasis on STAT3-driven epigenetic silencing of IRF8 in aged DCs/progenitors, loss of IL-12, tolerogenic bias, and restoration via alpha-DC1 (which reboots bidirectional instruction and breaks senescence loops).
Translational insight from decades in biotech R&D (BDMC reagents, cytometry,, molecular biology , ABI gene expression from PDARs /TaqMan assays for human genome, stem cell/nanotech concepts at Ki Biotechnology).
Digital Pathology, image analysis on next generation live tissue 8k resolution movies for micro environments
In summary, Blidy is the integrative bridge: early empirical discovery (flow cytometry/Tregs) + visionary systems/epigenetic thinking (2005) → co-authoring a unified DC-CD4 circuit model that explains aging, tolerance, and biological reboot strategies. This career arc makes his involvement especially valuable for D'Youville’s medical curriculum of nursing, pharmacy, OD medical. What foundational observations, chromatin-level mechanisms, and holistic self-regulation converge in modern medicine.

[Andy Blidy @ablidy]

@andrewcaravello Thanks for doing this , just pushing the envelope, very good answers ….

[Andrew Caravello, DO @andrewcaravello]

Great question(s) Andy...

You asked five questions that turn out to be one, and the answer runs down to something simpler and more testable than where it begins. A manufactured cell is accepted by the body in only two ways. It borrows a place where the immune system is already quiet, or it subtracts the response that would reject it. The deepest version of the answer is that the second route is not construction. It is subtraction, and there is human data showing it can be done.

The asymmetry that governs everything

The two states of the dendritic cell are not mirror images. The mature, IL-12-secreting cell reads danger actively and commits to arming only under real threat. The resting, tolerogenic cell runs the opposite logic but not symmetrically. It tolerizes largely by default, by the absence of danger, not by an active reading of safety. The tolerogenic gear is the less discriminating one, not the more cautious. A mature cell can refuse a weak threat. A locked tolerogenic cell cannot read an arriving danger signal and reconsider. That asymmetry is why you cannot simply flip a switch to tolerance and walk away.

Locking, and the Ebola worry

You were right to be wary, but the danger you pictured is the wrong one. The manufactured cell is short-lived. What persists is antigen-specific tolerance, aimed at the capsid, not a shutdown of presentation. That is the opposite of Ebola, which cripples dendritic cell function across the board and blinds the host to everything. The real resolution is that you never want to end in a locked, suppressed state. A quiet immune system is a failure mode. You want a fully competent system that has lost only its reaction to the capsid, which is not suppression held in place but subtraction made durable.

Off-the-shelf, hypoimmune, and the paradox specific to the instructor

The platform is real and bidirectional. The same line makes a cancer vaccine if you mature and license the cell, or a tolerance cell if you rest, load, and condition it. But making it universal hits a wall unique to the instructor. A donor cell carries foreign MHC, one of the strongest immune triggers. Hypoimmune editing solves foreignness for other cell types by deleting MHC and adding a do-not-eat-me signal, and it is already in human trials in allogeneic CAR-T [1] and in edited islet cells that survived without immunosuppression [2]. But that strategy eats itself in a dendritic cell. The cell’s entire function is to display antigen on MHC. Delete the MHC to hide it and you delete its only output. You can hide the cell or let it teach, not both. Strip class I and you also invite natural killer cells, which attack missing self, so the dark cell must buy back innate tolerance with more transgenes, each a failure point [3]. The honest path keeps only the presenting allele and accepts population banding. Which is why a tolerizing instructor is autologous, built from the patient’s own monocytes. That is the flaw you were hunting, and it is the reason the cell is the patient’s own.

Where the discrimination actually lives

The endpoint you want is a system that fires IL-12 at real threats but spares the capsid. But no single cell holds that knowledge. A cDC1 making IL-12 broadcasts an immunogenic signal across all its synapses at once [4,5]. It cannot make IL-10 at one and IL-12 at another in the same moment. The cell is essentially indiscriminate. What keeps it from attacking the capsid is not learned restraint. It is that the capsid has no army left to call. The discrimination lives in the repertoire and the regulatory cells, not in the instructor. The cDC1 is the executor of the forward gear, and it is safe toward the capsid only because the capsid-reactive effectors are gone.

The protocol, collapsed to its essentials

The patient already has cDC1s and never lost them. The protocol is a tolerizing course, a measurement that gates the therapy, an antibody-clearing adjunct where one is needed, and then the therapy, with redosing on both sides. Tolerize to delete the capsid-reactive repertoire, using the autologous capsid-loaded tolerogenic cell, likely as a redosed course rather than a single shot. Confirm deletion in the blood. Clear any standing anti-capsid antibody if the patient already carries it. Then deliver the vector, and redose it when expression needs topping up, because durable capsid tolerance is what makes that possible. From that point the patient’s own IL-12-secreting cDC1s are the discriminating forward gear by default. Tolerance here is subtraction. You remove one antigen’s army and leave the rest of the immune system intact.

The rheumatoid arthritis data, which carries the hardest step on the T-cell arm

The key claim is that the first step can delete rather than merely suppress, and the rheumatoid arthritis tolerogenic dendritic cell trials are the human evidence, made more convincing because RA is the harder case. Rheumavax used autologous monocyte-derived tolerogenic dendritic cells loaded with citrullinated peptides, given to HLA-risk RA patients who already carried established autoimmunity. A single dose produced, within a month, a reduction in effector T cells, an increased ratio of regulatory to effector T cells, lower inflammatory mediators, and reduced T cell responses to the specific peptide, without triggering disease flares [6]. A single dose moved an entrenched effector pool, so a redosed course is the obvious route to the deeper deletion the safety gate requires. Redosing serves two purposes at once, deepening the deletion and maintaining it over time so the vector itself can be given again.

This also sharpens what counts as a safe endpoint. It is not any anergy, since ordinary anergy is what a burst of IL-12 reverses. It is the stable, antigen-specific hyporesponsiveness and effector deletion these cells produce, which has been characterized as stable rather than labile [7]. The limit is that the field has shown feasibility and safety [8] but has not yet confirmed robust durable clinical tolerance, which is the focus of the Phase II trials now under way [9]. So depth is confirmed in each patient, not assumed, which is the job of the blood gate.

The antibody door, because it is what redosing actually turns on

This is the decisive arm, and the one to be most careful about, because the RA precedent that supports the T-cell claim points the other way here. Reducing effector T cells did not clear the anti-citrullinated autoantibodies, which in RA are persistent [6]. The antibody arm is harder than the killer arm, and it is two different problems depending on the patient.

For the AAV-naive patient, the problem is prevention, and this the dendritic cell can plausibly do. By shaping the follicular helper compartment toward follicular regulatory cells, the tolerizing cell can keep a capsid-specific antibody response from forming in the first place, before any memory B cells or plasma cells exist. This is the favorable case, and the one where the cell reaches a door a bottled cytokine pair cannot.

For the patient who already carries anti-AAV immunity, which is common and is precisely the patient who tends to need redosing [10], prevention is not enough and the dendritic cell does not reach the obstacle. Standing neutralizing antibody is made in part by long-lived plasma cells that sit in marrow niches and no longer depend on T-cell help, so no amount of follicular re-education clears them. That arm needs an adjunct the cell does not supply: transient IgG cleavage by an endopeptidase, the strategy already shown to let AAV reach target tissue in seropositive subjects [11], or a plasma-cell or B-cell-directed agent. The division of labor is that the adjunct forces the antibody door open transiently by removing the standing titer, and the tolerizing cell keeps it from slamming shut again by preventing the anamnestic response the next dose would otherwise raise. The cell does not open the antibody door. It keeps it from re-closing, which is the part that makes a second and third dose possible rather than a single bypass.

The capsid setting is therefore the easier, prophylactic case only for the naive patient. For the seropositive patient it is the harder established-response case, on both arms, no gentler than RA, met by the redosed deletional tolerization on the killer arm and by an antibody-clearing adjunct paired with antibody-preventive tolerization on the humoral arm.

The blood gate

Most of the panel exists now. The capsid T-cell response is already measured by interferon-gamma ELISPOT in AAV trials, because capsid-specific killers tracked with the early liver toxicity and loss of expression [12]. What you add is the question those tools were never asked. Run the capsid ELISPOT with and without the regulatory T cells removed. If depleting them unmasks a response that was not there, you have suppression and do not proceed. If none emerges, you have deletion. The most predictive safety test reproduces the danger in a dish, challenging the patient’s capsid-specific compartment with IL-12 and costimulation and watching whether any effector appears. Pair that with the anti-AAV neutralizing antibody titer, which is already standard, and which does double duty, since it stratifies the patient as naive or seropositive and so decides whether an antibody-clearing adjunct is even needed. The honest limit is that blood is a proxy for tissue, so a clean panel raises confidence sharply rather than to certainty, which is why the functional challenge matters most, since it reads behavior rather than location.

RPE in the eye, the contrast that proves the rule

Subretinal RPE replacement for geographic atrophy works partly because the eye is immune-privileged, and allogeneic RPE cells transplanted there have shown functional and structural improvement, with little clinical evidence of rejection, in early-phase trials [13,14]. But that tolerance is borrowed, not installed, and it is partial. Geographic atrophy is a complement-driven inflammatory disease, rejection in the eye is hard to detect, and the surgery breaches the barrier that grants the quiet. Borrowing privilege works only where privilege exists. In the liver and muscle where a vector goes, there is none to borrow, and you subtract the responders instead.

The whole answer in one line

A manufactured cell is accepted by borrowing quiet or by subtracting the response that would reject it. The eye borrows it and even there it frays. Hypoimmune editing installs acceptance by hiding the cell, which fails for the instructor, because hiding its MHC destroys the output it exists for. So the instructor stays autologous and presenting. And the tolerance it installs is not a fragile suppressive lock. It is the removal of one antigen’s army on the killer arm, confirmed in the blood, paired on the antibody arm with a transient clearing of standing titer and a dendritic cell that keeps the humoral door from re-closing. After that the patient’s own intact system does the discriminating for free, because a cDC1 with no capsid-reactive effectors to instruct simply presents the capsid and moves on. Every flaw you raised is a reason the work is done by a real, presenting, patient-matched cell that subtracts a response and guards the follicular door against its return, rather than by a molecule that can only suppress one signal, a hidden cell that cannot teach at all, or a borrowed privilege that lives in the eye and almost nowhere else.

The honest boundary

No one has yet run this in the exact form described, a redosed deletional tolerization gated by a repertoire-deletion and antibody panel, paired with an antibody-clearing adjunct in seropositive patients, before vector delivery and redelivery. It is a prediction, the same epistemic status as the article’s central claim. But the pieces are no longer assertions. Tolerogenic dendritic cells have reduced an antigen-specific effector compartment in humans in the harder autoimmune setting, IgG cleavage has already let AAV reach tissue in antibody-positive patients, and the rest follows from immunology the field understands. The discriminating instructor is not something you build. It is what deletion reveals, with the standing antibody cleared and kept from returning, and the blood test is what tells you it is safe to rely on it.

References

1. Hu X, Beauchesne P, Wang C, et al. Hypoimmune CD19 CAR T cells evade allorejection in patients with cancer and autoimmune disease. Cell Stem Cell. 2025. doi:10.1016/j.stem.2025.07.009.

2. Carlsson PO, et al. Survival of transplanted allogeneic beta cells with no immunosuppression. N Engl J Med. 2025. doi:10.1056/NEJMoa2503822.

3. Deuse T, Hu X, Gravina A, et al. Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients. Nat Biotechnol. 2019;37(3):252-258.

4. Mashayekhi M, Sandau MM, Dunay IR, et al. CD8alpha+ dendritic cells are the critical source of interleukin-12 that controls acute infection by Toxoplasma gondii tachyzoites. Immunity. 2011;35(2):249-259.

5. Theisen DJ, Murphy KM. The role of cDC1s in vivo: CD8 T cell priming through cross-presentation. F1000Res. 2017;6:98.

6. Benham H, Nel HJ, Law SC, et al. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci Transl Med. 2015;7(290):290ra87.

7. Raich-Regue D, Grau-Lopez L, Naranjo-Gomez M, et al. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur J Immunol. 2012;42(3):771-782.

8. Bell GM, Anderson AE, Diboll J, et al. Autologous tolerogenic dendritic cells for rheumatoid and inflammatory arthritis. Ann Rheum Dis. 2017;76(1):227-234.

9. Long EL, Stanway J, White M, et al. Autologous Tolerogenic Dendritic Cells for Rheumatoid Arthritis-2 (AuToDeCRA-2) study: protocol for a single-centre, experimental medicine study investigating the route of delivery and potential efficacy of autologous tolerogenic dendritic cell (TolDC) therapy for rheumatoid arthritis. Trials. 2025;26(1):278. doi:10.1186/s13063-025-08972-x.

10. Mingozzi F, Anguela XM, Pavani G, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med. 2013;5(194):194ra92.

11. Leborgne C, Barbon E, Verdera HC, et al. IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV antibodies. Nat Med. 2020;26(7):1096-1101.

12. Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med. 2006;12(3):342-347.

13. Banin E, et al. Exploratory optical coherence tomography (OCT) analysis in patients with geographic atrophy (GA) treated by OpRegen: results from the phase 1/2a trial. Invest Ophthalmol Vis Sci. 2023;64(8). ARVO E-Abstract. https://t.co/rXRuW5FLuD NCT02286089.

14. Klymenko V, Gonzalez Martinez OG, Zarbin M. Recent progress in retinal pigment epithelium cell-based therapy for retinal disease. Stem Cells Transl Med. 2024;13(4):317-331. doi:10.1093/stcltm/szae004.